ARNI联合EECP在PCI术后应用价值及对无创血流动力学指标再住院率的影响

doi:10.3969/j.issn.1006-6233.2024.07.024

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1179 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective: To investigate the efficacy of angiotensin receptor-neprilysin inhibitor (ARNI) combined with enhanced external counterpulsation (EECP) after percutaneous coronary intervention (PCI) and its impact on non-invasive hemodynamic parameters and readmission rate. Methods: One hundred patients with acute anterior myocardial infarction who successfully underwent emergency PCI treatment at the Department of Cardiology, Shandong First Affiliated Hospital of Shandong University from October 2022 to March 2024 were randomly divided into a trial group and a control group (50 patients each). The trial group received ARNI combined with EECP treatment, and the control group received angiotensin-converting enzyme inhibitor (ACEI) treatment. The two groups were compared in terms of cardiac function, quality of life scale (SF-36), hemodynamic parameters, and readmission rate. Results: Before treatment, there was no significant difference in cardiac function and hemodynamic parameters between the two groups (P>0.05). After 7 weeks of treatment, the levels of LVEDV, LVESV, NT-proBNP, ET-1, heart rate, SBP, DBP, RS, and CMR were decreased, while LVEF, CO, CI, LSI, LCI, AC, and COM were increased in both groups compared to before treatment (P<0.05). The magnitude of change was greater in the trial group than in the control group, and there was a significant difference between the two groups in these parameters (P<0.05). At 6-month follow-up, LVEDV, LVESV, NT-proBNP, ET-1, heart rate, SBP, DBP, RS, and CMR continued to decrease, while LVEF, CO, CI, LSI, LCI, AC, and COM continued to increase. However, the magnitude of change was smaller, and there was still a significant difference between the two groups in these parameters (P<0.05). Before treatment, there was no significant difference in the scores of physical function, physical function, emotional function, daily activities, mental health, overall health, social function, and physical pain on the SF-36 between the two groups (P>0.05). After 7 weeks of treatment, the scores of all of these items increased compared to before treatment (P<0.05), and the magnitude of change was greater in the trial group than in the control group. There was also a significant difference between the two groups in these items (P<0.05). At 6-month follow-up, the scores of these items continued to increase, but the magnitude of change was smaller. There was still a significant difference between the two groups in these items (P<0.05). The total major adverse cardiovascular event (MACE)-related readmission rate at 6 months after treatment was significantly different between the two groups (χ²=9.502, P=0.002). There was no significant difference in the readmission rate due to recurrent myocardial infarction or angina pectoris (χ²=0.340, P=0.560; χ²=2.152, P=0.142), but the readmission rate due to heart failure was significantly different (χ²=6.353, P=0.012). Conclusion: ARNI combined with EECP after PCI can improve cardiac function and patient health status, reduce resistance, reduce the incidence of adverse reactions after surgery, and thus reduce the readmission rate.

Key words： Percutaneous coronary intervention Sacubitril/valsartan Enhanced external counterpulsation Efficacy Hemodynamics Readmission rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WANG Fangming
	WANG Xiang
	QI Huaxin

Cite this article:

WANG Fangming,WANG Xiang,QI Huaxin. Efficacy of Angiotensin Receptor-Neprilysin Inhibitor Combined with Enhanced External Counterpulsation After Percutaneous Coronary Intervention and Its Impact on Non-invasive Hemodynamic Parameters and Readmission Rate[J]. HeBei Med, 2024, 30(7): 1185-1191.

URL:

http://www.hbyxzzs.cn/EN/10.3969/j.issn.1006-6233.2024.07.024 OR http://www.hbyxzzs.cn/EN/Y2024/V30/I7/1185

[1] Raeissadat SA,Javadi A,Allameh F.Enhanced external counterpulsation in rehabilitation of erectile dysfunction:a narrative literature review[J].Vasc Health Risk Manag,2018,3(14):393-399.
[2] 王媛,刘培良,苗磊.增强型体外反搏对冠状动脉粥样硬化性心脏病患者运动能力及血管内皮功能的影响[J].中国医刊,2022,57(8):844-847.
[3] 章慧慧,李亚平,辛国勇.沙库巴曲缬沙坦钠片联合阿托伐他汀治疗慢性充血性心力衰竭的效果及安全性观察[J].临床误诊误治,2022,35(5):13-16.
[4] 许文克,史永恩,孟祥斌,等.重组人脑利钠肽与沙库巴曲缬沙坦联合用药对急性心肌梗死伴急性心力衰竭患者疗效及血清半乳糖凝集素-3、正五聚蛋白-3水平的影响[J].世界临床药物,2021,42(5):381-387.
[5] Silvain J,Lattuca B,Beygui F,et al.Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS):a randomised,open-label,phase 3b trial[J].Lancet,2020,396(10264):1737-1744.
[6] 杨志军,顾宁.中医药治疗急性心肌梗死后心力衰竭研究进展[J].河北中医,2022,44(6):1030-1034,1040.
[7] 辛向斌,杨威,刘凯元,等.沙库巴曲缬沙坦用于STEMI行PCI术后HFrEF的效果[J].心血管病防治知识,2022,12(17):17-20.
[8] An J,Du Y,Li X,et al.Myocardial protective effect of Sacubitril-Valsartan on rats with acute myocardial infarction[J].Perfusion,2022,37(2):208-215.
[9] Shah A M,Claggett B,Prasan N,et al.Impact of sacubitril/valsartan compared with ramipril on cardiac structureand function after acute myocardial infarction:the paradise-miechocardiographic substudy[J].Circulation,2022,146(14):1067-1081.
[10] Ye F,Li H,Chen X,et al.Efficacy and safety of Sacubitril Valsartan in treating heart failure with midrange ejection fraction after acute myocardial infarction in diabetic patients[J].Medicine(Baltimore),2022,101(5):28729.